Do analysts rate CRON or SIGA?

Cronos Group currently has a consensus target price of $2.30, indicating a potential downside of 19.58%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts clearly believe Cronos Group is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CRON or SIGA?

In the previous week, Cronos Group had 2 more articles in the media than Siga Technologies. MarketBeat recorded 3 mentions for Cronos Group and 1 mentions for Siga Technologies. Cronos Group's average media sentiment score of 0.55 beat Siga Technologies' score of 0.14 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Siga Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SIGA or VOR?

Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 105.20%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vor Biopharma 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.82

Which has better valuation and earnings, SIGA or VOR?

Siga Technologies has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Siga Technologies $94.57M 2.93 $23.28M $0.27 14.30 Vor Biopharma N/A N/A N/A N/A N/A

Does the media prefer SIGA or VOR?

In the previous week, Vor Biopharma had 2 more articles in the media than Siga Technologies. MarketBeat recorded 3 mentions for Vor Biopharma and 1 mentions for Siga Technologies. Vor Biopharma's average media sentiment score of 0.23 beat Siga Technologies' score of 0.14 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SLDB or SIGA?

Solid Biosciences presently has a consensus target price of $17.00, suggesting a potential upside of 56.83%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Solid Biosciences is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SLDB or SIGA?

In the previous week, Solid Biosciences had 3 more articles in the media than Siga Technologies. MarketBeat recorded 4 mentions for Solid Biosciences and 1 mentions for Siga Technologies. Solid Biosciences' average media sentiment score of 0.72 beat Siga Technologies' score of 0.14 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Siga Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SIGA or ETON?

Eton Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 9.33%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eton Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media favor SIGA or ETON?

In the previous week, Siga Technologies and Siga Technologies both had 1 articles in the media. Eton Pharmaceuticals' average media sentiment score of 0.30 beat Siga Technologies' score of 0.14 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend EVO or SIGA?

Evotec currently has a consensus price target of $7.00, indicating a potential upside of 141.38%. Given Evotec's stronger consensus rating and higher probable upside, research analysts clearly believe Evotec is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, EVO or SIGA?

Siga Technologies has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 1.16 -$117.12M N/A N/A Siga Technologies $94.57M 2.93 $23.28M $0.27 14.30

Is EVO or SIGA more profitable?

Siga Technologies has a net margin of 21.58% compared to Evotec's net margin of -26.20%. Siga Technologies' return on equity of 10.60% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Siga Technologies 21.58% 10.60% 8.94%

Does the media favor EVO or SIGA?

In the previous week, Evotec had 3 more articles in the media than Siga Technologies. MarketBeat recorded 4 mentions for Evotec and 1 mentions for Siga Technologies. Evotec's average media sentiment score of 0.39 beat Siga Technologies' score of 0.14 indicating that Evotec is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Siga Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Siga Technologies (SIGA) Competitors

$3.86 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$4.04 +0.19 (+4.79%)

As of 07/2/2026 07:58 PM Eastern

Compare

SIGA vs. CRON, VOR, SLDB, ETON, and EVO

Should you buy Siga Technologies stock or one of its competitors? MarketBeat compares Siga Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Siga Technologies include Cronos Group (CRON), Vor Biopharma (VOR), Solid Biosciences (SLDB), Eton Pharmaceuticals (ETON), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry.

How does Siga Technologies compare to Cronos Group?

Cronos Group (NASDAQ:CRON) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Cronos Group currently has a consensus target price of $2.30, indicating a potential downside of 19.58%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts clearly believe Cronos Group is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Siga Technologies has lower revenue, but higher earnings than Cronos Group. Siga Technologies is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$146.59M	7.28	-$9.45M	$0.01	286.00
Siga Technologies	$94.57M	2.93	$23.28M	$0.27	14.30

Siga Technologies has a net margin of 21.58% compared to Cronos Group's net margin of -1.14%. Siga Technologies' return on equity of 10.60% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-1.14%	-1.26%	-1.20%
Siga Technologies	21.58%	10.60%	8.94%

Cronos Group has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 7.8% of Cronos Group shares are owned by insiders. Comparatively, 2.7% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cronos Group had 2 more articles in the media than Siga Technologies. MarketBeat recorded 3 mentions for Cronos Group and 1 mentions for Siga Technologies. Cronos Group's average media sentiment score of 0.55 beat Siga Technologies' score of 0.14 indicating that Cronos Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Siga Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cronos Group beats Siga Technologies on 9 of the 16 factors compared between the two stocks.

How does Siga Technologies compare to Vor Biopharma?

Siga Technologies (NASDAQ:SIGA) and Vor Biopharma (NASDAQ:VOR) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Siga Technologies has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.93	$23.28M	$0.27	14.30
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 105.20%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Siga Technologies has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 0.3% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Siga Technologies has a net margin of 21.58% compared to Vor Biopharma's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Vor Biopharma	N/A	N/A	N/A

In the previous week, Vor Biopharma had 2 more articles in the media than Siga Technologies. MarketBeat recorded 3 mentions for Vor Biopharma and 1 mentions for Siga Technologies. Vor Biopharma's average media sentiment score of 0.23 beat Siga Technologies' score of 0.14 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vor Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vor Biopharma beats Siga Technologies on 8 of the 13 factors compared between the two stocks.

How does Siga Technologies compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Solid Biosciences presently has a consensus target price of $17.00, suggesting a potential upside of 56.83%. Given Solid Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Solid Biosciences is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by insiders. Comparatively, 2.7% of Siga Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Solid Biosciences has a beta of 2.36, indicating that its stock price is 136% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

Siga Technologies has a net margin of 21.58% compared to Solid Biosciences' net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Siga Technologies	21.58%	10.60%	8.94%

In the previous week, Solid Biosciences had 3 more articles in the media than Siga Technologies. MarketBeat recorded 4 mentions for Solid Biosciences and 1 mentions for Siga Technologies. Solid Biosciences' average media sentiment score of 0.72 beat Siga Technologies' score of 0.14 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Siga Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Siga Technologies has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Siga Technologies	$94.57M	2.93	$23.28M	$0.27	14.30

Summary

Solid Biosciences and Siga Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Siga Technologies compare to Eton Pharmaceuticals?

Siga Technologies (NASDAQ:SIGA) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Siga Technologies has higher revenue and earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.93	$23.28M	$0.27	14.30
Eton Pharmaceuticals	$86.93M	11.82	-$4.60M	-$0.07	N/A

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Siga Technologies has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

In the previous week, Siga Technologies and Siga Technologies both had 1 articles in the media. Eton Pharmaceuticals' average media sentiment score of 0.30 beat Siga Technologies' score of 0.14 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eton Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 9.33%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Siga Technologies has a net margin of 21.58% compared to Eton Pharmaceuticals' net margin of -1.70%. Siga Technologies' return on equity of 10.60% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Summary

Siga Technologies beats Eton Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Siga Technologies compare to Evotec?

Evotec (NASDAQ:EVO) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Evotec currently has a consensus price target of $7.00, indicating a potential upside of 141.38%. Given Evotec's stronger consensus rating and higher probable upside, research analysts clearly believe Evotec is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evotec has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

In the previous week, Evotec had 3 more articles in the media than Siga Technologies. MarketBeat recorded 4 mentions for Evotec and 1 mentions for Siga Technologies. Evotec's average media sentiment score of 0.39 beat Siga Technologies' score of 0.14 indicating that Evotec is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Siga Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Siga Technologies has a net margin of 21.58% compared to Evotec's net margin of -26.20%. Siga Technologies' return on equity of 10.60% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Siga Technologies	21.58%	10.60%	8.94%

Siga Technologies has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	1.16	-$117.12M	N/A	N/A
Siga Technologies	$94.57M	2.93	$23.28M	$0.27	14.30

5.8% of Evotec shares are held by institutional investors. Comparatively, 55.4% of Siga Technologies shares are held by institutional investors. 1.0% of Evotec shares are held by company insiders. Comparatively, 2.7% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Evotec and Siga Technologies tied by winning 7 of the 14 factors compared between the two stocks.

Get Siga Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIGA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIGA vs. The Competition

Export

Metric	Siga Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$276.85M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	14.30	20.06	28.02	24.70
Price / Sales	2.93	360.33	540.37	99.49
Price / Cash	11.59	57.49	49.26	57.09
Price / Book	1.39	4.32	10.96	6.46
Net Income	$23.28M	$64.45M	$3.57B	$337.01M
7 Day Performance	-1.53%	2.97%	2.12%	1.69%
1 Month Performance	-10.23%	6.83%	5.25%	3.81%
1 Year Performance	-42.69%	29.07%	33.29%	23.90%

Siga Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIGA Siga Technologies	0.9216 of 5 stars	$3.86 flat	N/A	-42.7%	$276.85M	$94.57M	14.30	40	Analyst Downgrade Gap Down
CRON Cronos Group	1.2481 of 5 stars	$2.80 -1.9%	$2.30 -17.7%	+40.2%	$1.04B	$146.59M	279.78	450
VOR Vor Biopharma	2.2999 of 5 stars	$18.71 +0.6%	$42.25 +125.9%	-46.1%	$1.01B	N/A	N/A	140	News Coverage Analyst Upgrade Gap Down
SLDB Solid Biosciences	2.8614 of 5 stars	$10.24 +8.1%	$17.00 +66.0%	+117.8%	$1.01B	N/A	N/A	100	News Coverage Analyst Upgrade Gap Down
ETON Eton Pharmaceuticals	2.3849 of 5 stars	$36.72 0.0%	$41.00 +11.7%	+158.2%	$1.01B	$79.95M	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIGA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Siga Technologies (SIGA) Competitors

SIGA vs. CRON, VOR, SLDB, ETON, and EVO

How does Siga Technologies compare to Cronos Group?

Summary

How does Siga Technologies compare to Vor Biopharma?

Summary

How does Siga Technologies compare to Solid Biosciences?

Summary

How does Siga Technologies compare to Eton Pharmaceuticals?

Summary

How does Siga Technologies compare to Evotec?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA vs. The Competition

Siga Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Siga Technologies (SIGA) Competitors

SIGA vs. CRON, VOR, SLDB, ETON, and EVO

How does Siga Technologies compare to Cronos Group?

Do analysts rate CRON or SIGA?

Which has higher earnings and valuation, CRON or SIGA?

Is CRON or SIGA more profitable?

Which has more risk & volatility, CRON or SIGA?

Do insiders & institutionals believe in CRON or SIGA?

Does the media refer more to CRON or SIGA?

Summary

How does Siga Technologies compare to Vor Biopharma?

Which has better valuation and earnings, SIGA or VOR?

Do analysts prefer SIGA or VOR?

Which has more risk & volatility, SIGA or VOR?

Do insiders and institutionals believe in SIGA or VOR?

Is SIGA or VOR more profitable?

Does the media prefer SIGA or VOR?

Summary

How does Siga Technologies compare to Solid Biosciences?

Do analysts prefer SLDB or SIGA?

Do institutionals and insiders hold more shares of SLDB or SIGA?

Which has more volatility and risk, SLDB or SIGA?

Is SLDB or SIGA more profitable?

Does the media favor SLDB or SIGA?

Which has higher earnings and valuation, SLDB or SIGA?

Summary

How does Siga Technologies compare to Eton Pharmaceuticals?

Which has preferable valuation and earnings, SIGA or ETON?

Do insiders & institutionals believe in SIGA or ETON?

Which has more volatility and risk, SIGA or ETON?

Does the media favor SIGA or ETON?

Do analysts recommend SIGA or ETON?

Is SIGA or ETON more profitable?

Summary

How does Siga Technologies compare to Evotec?

Do analysts recommend EVO or SIGA?

Which has more risk & volatility, EVO or SIGA?

Does the media favor EVO or SIGA?

Is EVO or SIGA more profitable?

Which has stronger earnings & valuation, EVO or SIGA?

Do insiders and institutionals believe in EVO or SIGA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA vs. The Competition

Siga Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools